Human PKM antibody

ELISA, WB, ICC/IF

PKM2 (pyruvate kinase M2), its association with phospho-tyrosine (pTyr) motifs, enables cells to use predominantly aerobic glycolysis instead of oxidative phosphorylation. Also PKM2 suggest that this change benefits cancer cells by enabling them to redirect glycolytic metabolites away from oxidation and energy production and, instead, toward anabolic processes and biosynthesis. PKM2-mediated generation of the aerobic glycolytic phenotype, although wasteful in terms of glucose consumption and waste generation, could provide a variety of advantages for cancerous cells. In addition nuclear translocation of the tumor marker pyruvate kinase M2 induces programmed cell death.

Liquid in. Phosphate-Buffered Saline (pH 7.4) with 0.02% Sodium Azide, 10% glycerol

The antibody has been tested by ELISA, Western blot analysis and Immunofluorescence analysis to assure specificity and reactivity. Since application varies, however, each investigation should be titrated by the reagent to obtain optimal results. Recommended starting dilution for Western blot analysis is 1:1000 and Immunofluorescence is 1:250.

Monoclonal

Signal Transduction

Pyruvate kinase muscle isoform M2, Pyruvate kinase M1/2, Pyruvate kinase muscle, Cytosolic thyroid hormone-binding protein, CTHBP, Pyruvate kinase 2/3, Threonine-protein kinase PKM2, Thyroid hormone-binding protein 1, THBP1, Opa-interacting protein 3, OIP3, Tumor M2-PK, Tyrosine-protein kinase PKM2, PK2, PK3, PKM2, p58